Trexquant Investment LP Invests $2.53 Million in uniQure (NASDAQ:QURE)

Trexquant Investment LP purchased a new position in shares of uniQure (NASDAQ:QURE - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 143,080 shares of the biotechnology company's stock, valued at approximately $2,527,000. Trexquant Investment LP owned approximately 0.29% of uniQure as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Point72 Asset Management L.P. raised its stake in shares of uniQure by 336.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company's stock worth $4,816,000 after buying an additional 752,889 shares in the last quarter. Walleye Capital LLC acquired a new position in uniQure during the third quarter worth $444,000. FMR LLC raised its position in uniQure by 8,056.6% in the third quarter. FMR LLC now owns 350,572 shares of the biotechnology company's stock worth $1,728,000 after acquiring an additional 346,274 shares in the last quarter. Sanders Morris Harris LLC lifted its holdings in uniQure by 50.0% in the fourth quarter. Sanders Morris Harris LLC now owns 102,104 shares of the biotechnology company's stock valued at $1,803,000 after acquiring an additional 34,034 shares during the period. Finally, Franklin Resources Inc. purchased a new stake in shares of uniQure during the 3rd quarter worth $7,360,000. Institutional investors and hedge funds own 78.83% of the company's stock.

Insider Transactions at uniQure

In other news, CFO Christian Klemt sold 14,341 shares of uniQure stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $10.70, for a total value of $153,448.70. Following the completion of the sale, the chief financial officer now owns 152,372 shares of the company's stock, valued at $1,630,380.40. The trade was a 8.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Matthew C. Kapusta sold 28,341 shares of the company's stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total value of $291,628.89. Following the completion of the transaction, the chief executive officer now owns 651,454 shares of the company's stock, valued at $6,703,461.66. The trade was a 4.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 90,830 shares of company stock worth $961,401 over the last ninety days. 4.74% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on QURE shares. Royal Bank of Canada reiterated an "outperform" rating and issued a $24.00 price target on shares of uniQure in a report on Tuesday, January 21st. Wells Fargo & Company reduced their price target on shares of uniQure from $35.00 to $30.00 and set an "equal weight" rating for the company in a research report on Friday, February 28th. Stifel Nicolaus upped their price target on uniQure from $12.00 to $32.00 and gave the stock a "buy" rating in a report on Monday, December 16th. Mizuho raised their price objective on uniQure from $7.00 to $20.00 and gave the company a "neutral" rating in a research note on Thursday, December 19th. Finally, Chardan Capital began coverage on uniQure in a research report on Tuesday, April 1st. They set a "buy" rating and a $38.00 target price on the stock. One research analyst has rated the stock with a sell rating, three have issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $38.80.

uniQure Price Performance

QURE stock traded up $0.36 during trading on Friday, hitting $8.93. The stock had a trading volume of 856,678 shares, compared to its average volume of 1,683,917. The stock has a market cap of $482.91 million, a price-to-earnings ratio of -1.80 and a beta of 0.42. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. The company's 50 day moving average price is $12.28 and its two-hundred day moving average price is $11.07. uniQure has a 1-year low of $3.73 and a 1-year high of $19.18.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.